Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 73Rituximab 59Specimen Handling 49Biopsy 42Doxorubicin 41Vincristine 40Magnetic Resonance Spectroscopy 39Prednisone 36venetoclax 28obinutuzumab 27fludarabine 26ibrutinib 22Methotrexate 22Dexamethasone 21Cytarabine 21Lenalidomide 20blinatumomab 19Etoposide 19merphos 17zanubrutinib 16acalabrutinib 16prednylidene 15fludarabine phosphate 15deltacortene 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13CT-P10 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vorinostat × Lymphoid × 30 days × Clear all
NCT05848687 2026-06-03

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Stanford University

Phase 1/2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02943642 2026-05-18

Resimmune®

Virogen Biotechnology Inc.

Phase 2 Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡